Business Context and Reporting Period
Company: Eli Lilly and Company (LLY)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Lilly operates as a single segment focused on the discovery, development, manufacturing, and marketing of human pharmaceutical products. The company's portfolio spans cardiometabolic health, oncology, immunology, and neuroscience. Key products include Mounjaro, Zepbound, Trulicity, Verzenio, and Taltz.
Key Financial Metrics
| Metric (in millions, except per share) | 2024 | 2023 | Change |
|---|---|---|---|
| Revenue | $45,042.7 | $34,124.1 | +32% |
| Net Income | $10,590.0 | $5,240.4 | +102% |
| Earnings Per Share (Diluted) | $11.71 | $5.80 | +102% |
| Gross Margin | $36,624.4 | $27,041.9 | +35% |
| Gross Margin % | 81.3% | 79.2% | +2.1 pts |
| Operating Cash Flow | $8,817.9 | $4,240.1 | +108% |
| Total Debt | $33,644.2 | $25,225.3 | +33% |
| Cash and Cash Equivalents | $3,268.4 | $2,818.6 | +16% |
| Capital Expenditures | $5,057.8 | $3,447.6 | +47% |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by volume increases in Mounjaro (+124%), Zepbound (launched Nov 2023, +$4.75B), and Verzenio (+37%). This was partially offset by a 26% decline in Trulicity revenue due to competitive dynamics and supply constraints.
- Profitability: Net income doubled, fueled by a 2.1 percentage point increase in gross margin (favorable product mix and higher realized prices) despite higher operating expenses.
- Expenses:
- R&D: Increased 18% to $10.99B due to investments in early and late-stage portfolios.
- Acquired IPR&D: $3.28B charge in 2024, primarily related to the acquisition of Morphic Holding, Inc.
- Special Charges: $860.6M in asset impairment, restructuring, and other special charges, including a $435M litigation charge and an intangible asset impairment for Vitrakvi.
- Debt: Total debt increased by $8.42B to $33.64B, reflecting new issuances to fund business development and general purposes.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Supply Chain: Demand for incretin medicines (Mounjaro/Zepbound) exceeded production at various times in 2024. While U.S. supply currently exceeds demand, the company is expanding manufacturing capacity globally to meet future needs.
- Capital Allocation: Completed a $5.0B share repurchase program in 2024 and authorized a new $15.0B program in December 2024. Dividends increased to $1.50 per share quarterly (indicating $6.00 annual rate for 2025).
- Investments: Capital expenditures are expected to remain meaningfully higher over the next several years to support manufacturing expansion.
Risks and Contingencies:
- Regulatory & Pricing: The Inflation Reduction Act (IRA) poses significant pricing risks. Jardiance was selected for government-set prices effective 2026, with a 66% discount announced. The company expects additional products to be selected in future years.
- Intellectual Property: Reliance on a few key products (Mounjaro, Trulicity, Zepbound accounted for 48% of 2024 revenue) creates concentration risk. Trulicity faces patent and data protection expirations in the coming years.
- Legal: Significant litigation includes insulin pricing lawsuits, 340B program disputes, and product liability claims related to incretin medicines. The company is self-insured for most litigation liabilities.
- Counterfeit Products: Increased production of counterfeit and compounded incretins poses risks to patient safety and revenue.
Investor Verification Checklist
- Supply Capacity: Verify the timeline and success of manufacturing expansions to ensure demand for tirzepatide (Mounjaro/Zepbound) can be met without further shortages.
- IRA Impact: Monitor future HHS selections for price negotiation under the Inflation Reduction Act and the specific impact on Jardiance and other major products.
- Patent Expirations: Track the timeline for Trulicity patent expirations and the potential erosion of revenue from generic/biosimilar competition.
- Acquisition Integration: Assess the commercial progress and integration of the Morphic acquisition (MORF-057) following the $2.55B IPR&D charge.
- Legal Exposure: Review updates on insulin pricing litigation and incretin product liability claims, given the company's self-insured status.